Phase 1 Study of LTZ-301 for Non-Hodgkin Lymphoma
This study is testing a new treatment called LTZ-301 for adults with non-Hodgkin lymphoma that has returned or not responded to at least two previous treatments. This is a first-in-human, Phase 1 study, meaning it's the first time LTZ-301 is being given to people. Researchers want to see how safe LTZ-301 is and how well your body tolerates it. They will also look at how the drug moves through your body and if it shows any signs of fighting cancer. LTZ-301 is a bispecific antibody that targets cancer cells. The study plans to enroll 42 participants. The current status of this study is unclear.
- Study design
- This is a Phase 1, multicenter, open-label study, meaning you and your doctors will know you are receiving LTZ-301. It plans to enroll 42 adult participants.
- What's involved
- You would receive LTZ-301 intravenously (through a vein) in cycles. Dosing frequency changes over the first few cycles, starting weekly and then moving to every two or three weeks.
- Compensation
- Not stated in the trial record.
- Follow-up
- Your safety and tolerability will be measured for up to 54 weeks.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma
At a glance
Conditions
Where it's being run
6 sites across 5 statesWho to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Safety and TolerabilityUp to 54 weeks
To determine the incidence of adverse events according to CTCAE v5.0 and meeting protocol defined and dose limiting toxicity criteria.